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ABSTRACT 
Introduction: Respiratory syncytial virus 
(RSV) is a major cause of lower respiratory 
tract infections in infants and young children 
and the leading cause of hospitalization in 
infants aged <1 year. Methods: We examined 
trends in RSV hospitalization (RSVH) among 
infants from 1998 to 2006, using the United 
States (US) National Hospital Discharge Survey 
(NHDS) database. RSVH was defined by the 
International Classification of Diseases, 9th 
Revision, Clinical Modification (ICD-9-CM) 
codes 079.6 (RSV), 466.11 (acute bronchiolitis 
due to RSV), and 480.1 (pneumonia due to 
RSV). Age at the time of hospitalization was 
determined using NHDS birth records; RSVH 
rates were analyzed for infants grouped 
into three age cohorts (<3 months, 3 to 6 
months, and >6 to <24 months). Trends in 
hospitalization rates were evaluated using 
linear regression. Relative rates (RR) and 95% 
confidence intervals (CI) were computed to 
compare average RSVH rates for infants across 
age-specific groups. The annual proportion of 
RSVH by age group was also calculated. Results: 
Approximately 1.1 million (90,000-147,000 per 
year) RSVHs in predominantly term children 
aged <24 months were analyzed. Compared 
with children aged >6 to <24 months, rates for 
RSVH were significantly higher among infants 
aged <3 months (RR, 7.38; 95% CI, 7.35-7.41) 
and infants aged 3 to 6 months (RR, 5.28; 
95% CI, 5.26-5.29). The proportion of RSVH 
in the first year of life was lowest among 
infants aged <1 month (0.9%). The greatest 
proportion of RSVH was observed in children 
aged 3 to 6 months (14%-23% RSVH per year; 
chi-square P<0.0001). When the definition of 
RSVH was expanded to include unspecified 
hospitalizations for acute bronchiolitis, 
similar results were observed. Conclusion: RRs 
were highest among the <3- month and 3- to 
6-month age groups. The highest proportion 
of RSVH was among the 3- to 6-month age 
group. Analysis of the impact of RSV season, 
clinical practices, and other factors on these 
trends is warranted.
Keywords: age; hospitalization; respiratory 
syncytial virus; young infants 
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INTRODUCTION
Respiratory syncytial virus (RSV) is recognized 
as the leading cause of serious lower respiratory 
tract disease in infants and young children.1-3
RSV in infants and children accounts for 
approximately 50%-80% of winter bronchiolitis 
and 30%-60% of  winter  pneumonia 
hospitalizations in the United States (US).1 As 
many as 125,000 infants and young children 
are hospitalized in the US each year owing to 
severe RSV disease, and approximately 80% 
of hospitalizations involve term infants.3-5
Palivizumab was licensed in 1998 for the 
prevention of RSV disease in high-risk infants. 
We analyzed data from the US National Hospital 
Discharge Survey (NHDS) to examine temporal 
trends in RSV hospitalizations (RSVH) among 
children <2 years of age. Although the NHDS 
does not have information on treatment or 
prophylaxis, we were interested in exploring 
trends in RSVH after 1998, following the 
introduction of palivizumab.
MATERIALS AND METHODS
Data from the US NHDS, a nationally 
representative cohort of inpatient RSVHs in 
children aged <24 months, were analyzed to 
examine trends in RSVH rates by chronologic 
age (CA) from 1998 (the launch of palivizumab) 
to 2006. The proportion of RSVHs out of all 
hospitalizations was calculated for each year 
between 1998 and 2006 to examine the burden 
that RSVH imposes on the US healthcare system. 
Infants and children were stratified into three 
mutually exclusive CA groups: <3 months, 3 
to 6 months, and >6 to <24 months. Because 
testing for RSV is not consistently performed in 
the hospital setting, we repeated the analyses 
with an expanded definition of RSV, to include 
unspecified acute bronchiolitis (AB).
NHDS
Administered annually since 1965, the NHDS 
is the largest available nationally representative 
survey of inpatient hospitalizations in nonfederal 
acute care hospitals. Patient discharge records 
from hospitals with ≥6 beds for inpatient use 
were included in the survey. A three-stage 
probability design based on geographic area, 
hospital, and discharge data was used to select 
sample data. Data were weighted to produce 
national estimates. Variables collected at each 
discharge included patient demographics (age, 
sex, race, marital status); hospital characteristics 
(geographic location, number of beds); inpatient 
hospitalization characteristics (up to seven 
International Classification of Diseases, 9th 
Revision, Clinical Modification [ICD-9-CM]-
coded diagnoses); days of hospitalized care; 
patient disposition; month, day, and year of 
discharge; primary and secondary expected 
source of payment; and type of admission and 
procedures. Patient identifiers were removed to 
ensure patient anonymity.6
Hospitalization Due to RSV
An RSVH was defined as including ≥1 RSV-related 
ICD-9-CM code among up to seven discharge 
diagnosis codes in the hospital discharge record. 
For this study, RSV-related ICD-9-CM codes 
included 079.6 (RSV), 466.11 (AB due to RSV), or 
480.1 (pneumonia due to RSV), in the hospital 
discharge records. The current study analyzed 
data from 1998, as RSV codes were first introduced 
in 1996, thus allowing a 2-year period to ensure 
nationwide hospital adoption of the new codes.
RSV and AB
Testing for RSV is often not consistently performed 
in the hospital setting, and presumptive RSV 
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lower respiratory infections may frequently be 
coded as unspecified AB. We therefore expanded 
our definition of RSVH to include unspecified AB 
hospitalizations (ABH) and conducted additional 
analyses based on this expanded definition of 
the disease (RSVH/ABH). Specifically, a hospital 
discharge with at least one diagnosis code of 
079.6 (RSV) 466.XX (AB, unspecified), or 480.1 
(pneumonia due to RSV) was considered as RSVH/
ABH.
Age
The birth month, day, and year were abstracted 
from the hospital records. Age at hospitalization 
was calculated by subtracting the birth date from 
the hospital admission date. For purposes of 
analyses, CA was categorized into three groups 
(<3 months, 3 to 6 months, and >6 to <24 
months). Age categories were chosen based on 
the American Academy of Pediatrics guidance 
for RSV prophylaxis use.7
Statistical Methods
Analyses were limited to children <24 months. 
Hospital admissions related to birth were 
excluded. Simple descriptive statistics were 
calculated. All analyses were stratified by age 
categories (<3 months, 3 to 6 months, and >6 
to <24 months). All statistical analyses were 
performed using Statistical Analysis Software 
version 9.1 (SAS Institute Inc., Cary, NC, 
USA).
Incidence Calculations
Incidence rates of RSVH were calculated as the 
estimated number of new RSVHs per 1000 children 
for each year and age category of interest. The 
number of RSVHs was determined by summing the 
weighted values for each observation in the NHDS; 
denominator values were estimated by the number 
of live births for children using the natality data 
for the corresponding year. Thus, the number of 
children aged 0 to <3 months and 3 to 6 months 
were each estimated by taking the annual estimate 
of live births and multiplying by 0.25. The number 
of children aged >6 to <24 months was estimated 
by taking the annual estimate of live births and 
multiplying by 1.5. Trends were calculated using 
linear regression.
Relative Rates
Crude regression models were built to compare 
the incidence of RSVH in older children (>6 to 
<24 months of age) with younger children (<3 
months, and 3 to 6 months of age). Relative rates 
(RR) and associated 95% confidence intervals 
(CI) were reported. 
Annual Proportions
The annual proportion of hospitalizations due 
to RSV was calculated to estimate the burden 
that RSV imposes on the healthcare system for 
the three age categories. Annual proportions of 
RSVH were calculated by dividing the number 
of RSVHs (as defined above) by the total 
hospitalizations for that year for each of the age 
categories of interest. Incidence rates, RR, and 
annual proportion analyses were repeated for 
RSVH/ABH as the outcome of interest.
RESULTS
Hospitalization Due to RSV
There were 1,102,293 (90,000-147,000 per 
year) hospitalizations due to RSV in children 
<24 months of age identified between 1998 and 
2006. Most children were <3 months (40%), male 
(57%), and white (61%) and lived in the southern 
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region of the US (37%; Table 1). Compared with 
children aged >6 to <24 months, rates for RSVH 
were significantly higher for infants aged <3 
months (RR, 7.38; 95% CI, 7.35-7.41) and infants 
aged 3 to 6 months (RR, 5.28; 95% CI, 5.26-
5.29). However, the incidence of RSVH showed 
a nonsignificant decrease for all age groups 
from 1998 to 2006 (–0.4 per 1000 children per 
year; P=0.784). Between 2000 and 2006, RSVH 
decreased at a faster rate (age <3 months, –3.5 per 
1000 children per year; age 3 to 6 months, –3.3 
per 1000 children per year; age >6 to <24 months, 
–0.35 per 1000 children per year), with the most 
significant decrease (P=0.026) for children <3 
months of age (Figure 1).
Between 1998 and 2006, the annual 
proportion of RSVHs varied from 8% to 12% per 
year for children aged <3 months, and 6% to 
10% per year for children aged >6 to <24 months. 
The highest proportion of hospitalizations due to 
RSV (14% to 23% per year) occurred in children 
aged 3 to 6 months (chi-square, P<0.0001; 
Figure 2). We also examined the proportion of 
hospitalizations by CA (in months) for all study 
years combined (1998 to 2006) to explore the 
appropriateness of the age groups analyzed (ie, 
<3 months, 3 to 6 months, >6 to <24 months). 
Approximately 9% of hospitalized infants aged 
≤1 month had RSV. In contrast, approximately 
20% of hospitalized infants aged 2 to 4 months 
had RSV, and approximately 16% of hospitalized 
children aged 5 to 8 months had RSV. After 8 and 
12 months of age, the proportion of hospitalized 
children with RSV fell to approximately 10% and 
7%, respectively (Figure 3).
Hospitalizations Due to RSV and AB
When the definition of RSVH was expanded 
to include unspecified ABH, the total number 
of hospitalizations for children aged <24 
months between 1998 and 2006 increased to 
1,928,520. Results for RR, annual incidences, 
and annual proportions by CA were similar 
Characteristic RSV hospitalizations, n (%)
Age, months 
   <3 
   3 to 6 






   Male 





   White 
   Black 






   Northeast 
   Midwest 
   South 






Table 1. Characteristics of children aged <24 months with RSV hospitalizations* from 1998 to 2006.
RSV= respiratory syncytial virus. *Newborn hospitalizations were excluded.
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Figure 2. Proportion of RSV hospitalizations among all hospitalizations stratified by age group: 1998-2006.  
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Figure 3. Proportion of RSV hospitalizations by chronologic age: 1998-2006. RSV=respiratory syncytial virus. 
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for RSVH and RSVH/ABH. Rates for RSVH/
ABH were significantly higher for infants aged 
<3 months (RR, 5.45; 95% CI, 5.43-5.47) and 
infants aged 3 to 6 months of age (RR, 5.11; 
95% CI, 5.10-5.13), compared with children 
aged >6 to <24 months. As with RSVH, RSVH/
ABH rates declined faster after the year 2000 
for children aged <3 months (−5.3 per 1000 
children per year; P=0.008) and children 
aged 3 to 6 months (−7.0 per 1000 children 
per year; P=0.028) compared with children 
aged >6 to <24 months (0.03 per 1000 
children per year; P=0.446); the percentage 
of RSVHs/ABHs was greatest for those aged 
3 to 6 months (30% to 40% of total annual 
hospitalizations, compared with 14% to 20% 
of annual hospitalizations in the other two 
age categories), and for those with a CA of 
2 to 8 months (27% to 37% of total annual 
hospitalizations; data not shown).
DISCUSSION
RSV lower respiratory tract infection remains 
the most important cause of rehospitalization 
in infants and young children.1,5 Consistent 
with results from other studies,1-5 we found that 
RR of RSVH were significantly higher (P<0.001) 
in children ≤6 months of age compared 
with children with a CA of >6 months. The 
incidence of RSVH appeared to decrease in a 
nonsignificant fashion among children of all 
ages from 1998 to 2006. The only significant 
decrease in hospitalization rates was observed 
in infants with a CA of <3 months (P=0.026). 
This may reflect greater protection due to the 
implementation of the 3-month maternity leave 
and increased awareness of the importance of 
protection from RSV in this very young age 
group. The overall decreasing trend for RSVH in 
all infants and children may also be a reflection 
of the shift towards outpatient management of 
RSV disease.4
This study also assessed annual proportions 
by month of CA as an estimate of the burden 
imposed by RSVH. The proportion of RSVH in 
the first year of life was lowest in infants with a 
CA of <1 month (0.9%). We speculate that this 
may be due to a combination of diminished 
exposure to RSV, and high maternal antibody 
levels.8,9 The largest proportion of RSVH occurred 
in children with a CA of 2 to 4 months (20%) 
and 5 to 8 months (16%). Additional RSVH risk 
factors in these groups may include immunologic 
vulnerability to severe RSV illness due to the 
nadir in circulating maternal immunoglobulin 
G antibody9 and increased RSV exposure of 
older infants in situations such as day care.8 The 
proportion of RSVH remained high for children 
through the first year of life: 13% at a CA of 8 
months, and 10% at 11 months.
It has been reported that RSV testing is not 
performed in up to 30% of suspected cases.4 We 
therefore expanded our definition of RSVH to 
include unspecified AB and reanalyzed the data 
using the expanded definition of the disease. For 
all analyses, results were similar. We found no 
evidence that potential misclassification of RSV 
or frequency of RSV testing played an important 
role in the trends we observed.
The strengths of this study include its large 
sample size, records-based data collection, 
broad geographic scope, and prolonged period 
of surveillance (eight RSV seasons). However, a 
number of study limitations exist. RSV testing 
was not routinely employed. Furthermore, we 
could not validate the type of RSV test used 
for those who were tested. This study was also 
historical in nature, and the hospital discharge 
data used could have included coding errors.
We believe that the findings from this study 
are an important step in the further delineation 
of those infants and children at highest risk for 
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RSVH. Further studies are warranted, as such 
information could have important implications 
for future development of guidelines for RSV 
immunoprophylaxis and vaccines.
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